LucidQuest’s Post

Thoughts on this? >> Pfizer and BioNTech say GSK's Covid patent suit is 'groundless' >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical

Thoughts on this? >> GSK accuses Pfizer and BioNTech of mRNA patent infringement >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical

Stay ahead in the pharma industry with our comprehensive DrugPatentWatch Week in Review. Get insights into the latest patent expirations, new drug approvals, and market trends. Equip yourself with the knowledge to make informed decisions. #PharmaIndustry #PatentExpiration #DrugApprovals #WeeklyUpdate

Thoughts on this? >> Liquidia wins with Supreme Court decision to not review Yutrepia-Tyvaso patent battle >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #biotech #pharma

Thoughts on this? >> Liquidia wins with Supreme Court decision to not review Yutrepia-Tyvaso patent battle >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #pharma #healthcare

The FDA 505b2 Pathway was born out of the Hatch-Waxman Amendments in 1984, and has completely revamped the drug approval process. It's like a secret weapon that allows companies to tap into third-party studies, saving both application time and costs. This 505b2 Pathway is no ordinary route; it's a hybrid of the 505b1 and 505j. Imagine the possibility of bidding farewell to nonclinical studies, reducing risks, enjoying a streamlined application process, and faster development: https://lnkd.in/dYfY8uSq #pharmaceutical #3dprinting #3dprintingtechnology #medicalinnovation #medicaltechnology #medicaltech

💼 Legal Update: Moderna vs. Pfizer/BioNTech Patent Dispute 💼 The UK High Court has delivered a mixed verdict in the ongoing patent dispute between Moderna and its competitors, Pfizer and BioNTech. 📌 The court invalidated Moderna’s EP 3 718 565 patent but upheld the validity and infringement of EP 3 590 949. This decision requires Pfizer and BioNTech to compensate Moderna for using their patented technology after March 7, 2022. 🏆 📌 This ruling is part of a broader series of global lawsuits initiated by Moderna in 2022, covering multiple countries, including Germany, the Netherlands, Belgium, Ireland, and the UK. The core of the dispute revolves around Moderna’s RNA technology and respiratory virus vaccine patents. While the High Court's decision is subject to #appeal, it underscores the critical importance of protecting intellectual property in the pharmaceutical industry. Both parties have expressed intentions to appeal some aspects of the judgment. Stay tuned for further updates as this case progresses! #Moderna #Pfizer #BioNTech #PatentLaw #Pharmaceuticals #Innovation #LegalNews

A recent Federal Circuit decision indicates that public statements by a generic drug manufacturer can be relied upon to show induced infringement of method of treatment patents, even where the generic uses a "skinny label." Click below to download our Commentary, which analyzes the decision and its implications for drug manufacturers. Anthony Insogna Sarah Geers Matt Hertko Andrea Jeffries Jason Winchester #intellectualproperty #patentlaw #pharmaceuticals

Thoughts on this? >> Jury says AstraZeneca should pay Pfizer $107M+ over Tagrisso infringement >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #productmarketing

A strong #IP search strategy upfront can set your #pharmaceutical substance up for success. Register for our July 24 webinar with Managing IP and learn how: https://ow.ly/hor350SuIYE